Cancer treatment strategies targeting sphingolipid metabolism

Advances in Experimental Medicine and Biology

Volumn 688, Issue , 2010, Pages 185-205

  Oskouian, Babak ^b   Saba, Julie D ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CERAMIDE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; CURCUMIN; DAUNORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FENRETINIDE; FINGOLIMOD; IMATINIB; NONSTEROID ANTIINFLAMMATORY AGENT; OGT 2378; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MDM2; RESVERATROL; SAFINGOL; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TAMOXIFEN; TELOMERASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BLADDER CANCER; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE ARREST; CELL FATE; CELL MIGRATION; COLON CANCER; DRUG CYTOTOXICITY; DRUG TARGETING; HUMAN; LIPID METABOLISM; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; TELOMERE; TUMOR VASCULARIZATION; ANIMAL; BIOLOGICAL MODEL; CELL CYCLE; DRUG EFFECT; METABOLISM; NEOPLASM; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL CYCLE; CERAMIDES; HUMANS; LYSOPHOSPHOLIPIDS; MODELS, BIOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION; SPHINGOLIPIDS; SPHINGOSINE;

EID: 78049510823     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6741-1_13     Document Type: Article

References (187)

1. Morales A, Lee H, Goñi F et al. Sphingolipids and cell death. Apoptosis 2007; 12:923-39. (Pubitemid 46653290)
2. Futerman A, Riezman H. The ins and outs of sphingolipid synthesis. Trends Cell Biol 2005; 15:312-8. (Pubitemid 40805327)
3. Kihara A, Mitsutake S, Mizutani Y et al. Metabolism and biological functions of two phosphorylated sphingolipids, sphingosine 1-phosphate and ceramide 1-phosphate. Prog Lipid Res 2007; 46:126-44. (Pubitemid 46661866)
4. Prinetti A, Chigorno V, Mauri L et al. Modulation of cell functions by glycosphingolipid metabolic remodeling in the plasma membrane. J Neurochem 2007; 103(Suppl 1):113-25.
5. Zeidan Y, Hannun Y. Translational aspects of sphingolipid metabolism. Trends Mol Med 2007; 13:327-36. (Pubitemid 47126985)
6. Kitatani K, Idkowiak-Baldys J, Hannun YA. The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal 2007.
7. Murph M, GB M. Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. Expert Rev Mol Med 2007; 9:1-18.
8. Kolesnick RN, Goni FM, Alonso A. Compartmentalization of ceramide signaling: Physical foundations and biological effects. J Cell Physiol 2000; 184(3):285-300. (Pubitemid 30625491)
9. Itoh M, Kitano T, Watanabe M et al. Possible role of ceramide as an indicator of chemoresistance: Decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin Cancer Res 2003; 9(1):415-23. (Pubitemid 36109759)
10. Okazaki T, Bell R, Hannun Y. Sphingomyelin turnover induced by vitamin D3 in HL-60 cells. J Biol Chem 1989; 264(32):19076-80.
11. Liu B, Obeid L, Hannun Y. Sphingomyelinases in cell regulation. Semin Cell Dev Biol 1998; 8(3):311-22. (Pubitemid 127346646)
12. Valaperta R, Chigorno V, Basso L et al. Plasma membrane production of ceramide from ganglioside GM3 in human fibroblasts. FASEB J 2006; 20:1227-9.
13. Nikolova-Karakashian M, Merril AH Jr. Ceramidases. Methods Enzymol 2000; 311(Part A):194-207.
14. Olivera A, Spiegel S. Sphingosine kinase: A mediator of vital cellular functions. Prostaglandins Other Lipid Mediat 2001; 64(1-4):123-34. (Pubitemid 32452286)
15. Le Stunff H, Peterson C, Liu H et al. Sphingosine-1-phosphate and lipid phosphohydrolases. Biochim Biophys Acta 2002; 1582(1-3):8-17. (Pubitemid 34634106)
16. Mandala SM, Thornton R, Tu Z et al. Sphingoid base 1-phosphate phosphatase: A key regulator of sphingolipid metabolism and stress response. Proc Natl Acad Sci USA 1998; 95(1):150-5. (Pubitemid 28103922)
17. Bandhuvula P, Saba J. Sphingosine-1-phosphate lyase in immunity and cancer: Silencing the siren. Trends Mol Med 2007; 13(5):210-7. (Pubitemid 46687129)
18. Watanabe M, Kitano T, Kondo T et al. Increase of nuclear ceramide through caspase-3-dependent regulation of the "sphingomyelin cycle" in Fas-induced apoptosis. Cancer Res 2004; 64(3):1000-7. (Pubitemid 38176903)
19. Clarke C, Snook C, Tani M et al. The extended family of neutral sphingomyelinases. Biochemistry 2006; 45:11247-56. (Pubitemid 44453973)
20. Jayadev S, Liu B, Bielawska A et al. Role for ceramide in cell cycle arrest. J Biol Chem 1995; 270(5):2047-52.
21. Yoshimura S, Banno Y, Nakashima S et al. Ceramide formation leads to caspase-3 activation during hypoxic PC12 cell death. Inhibitory effects of Bcl-2 on ceramide formation and caspase-3 activation. J Biol Chem 1998; 273(12):6921-7. (Pubitemid 28160357)
22. Liu Y, Wada R, Yamashita T et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 2000; 106(8):951-61.
23. Takeda Y, Tashima M, Takahashi A et al. Ceramide generation in nitric oxide-induced apoptosis. Activation of magnesium-dependent neutral sphingomyelinase via caspase-3. J Biol Chem 1999; 274(15):10654-60.
24. Mansat V, Laurent G, Levade T et al. The protein kinase C activators phorbol esters and phosphatidylserine inhibit neutral sphingomyelinase activation, ceramide generation and apoptosis triggered by daunorubicin. Cancer Res 1997; 57(23):5300-4. (Pubitemid 27516367)
25. Sawada M, Nakashima S, Banno Y et al. Ordering of ceramide formation, caspase activation and Bax/ Bcl-2 expression during etoposide-induced apoptosis in C6 glioma cells. Cell Death Differ 2000; 7(9):761-72.
26. Hara S, Nakashima S, Kiyono T et al. p53-Independent ceramide formation in human glioma cells during gamma-radiation-induced apoptosis. Cell Death Differ 2004; 11:853-61. (Pubitemid 39139744)
27. Jayadev S, Linardic C, Hannun Y. Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor a. J Biol Chem 1994; 269(8):5757-63. (Pubitemid 24242948)
28. Schütze S, Machleidt T, Krönke M. The role of diacylglycerol and ceramide in tumor necrosis factor and interleukin-1 signal transduction. J Leukoc Biol 1994; 56:533-41. (Pubitemid 24348808)
29. Lei X, Zhang S, Bohrer A et al. The group VIA calcium-independent phospholipase A2 participates in ER stress-induced INS-1 insulinoma cell apoptosis by promoting ceramide generation via hydrolysis of sphingomyelins by neutral sphingomyelinase. Biochemistry 2007; 46:10170-85. (Pubitemid 47381276)
30. Bruno A, Laurent G, Averbeck D et al. Lack of ceramide generation in TF-1 human myeloid leukemic cells resistant to ionizing radiation. Cell Death Differ 1998; 5:172-82. (Pubitemid 28356554)
31. Maddens S, Charruyer A, Plo I et al. Kit signaling inhibits the sphingomyelin-ceramide pathway through PLC gamma 1: Implication in stem cell factor radioprotective effect. Blood 2002; 100:1294-301. (Pubitemid 34864284)
32. Liu B, Hannun Y. Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione. J Biol Chem 1997; 272:16281-7. (Pubitemid 27276449)
33. Marchesini N, Hannun Y. Acid and neutral sphingomyelinases: Roles and mechanisms of regulation. Biochem Cell Biol 2004; 82:27-44. (Pubitemid 38580872)
34. Schneider PB, Kennedy EP. Sphingomyelinase in normal human spleens and in spleens from subjects with Niemann-Pick disease. J Lipid Res 1967; 8(3):202-9.
35. Santana P, Pena L, Haimovitz-Friedman A et al. Acid sphingomyelinase- deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 1996; 86:189-99. (Pubitemid 26286102)
36. Zundel W, Giaccia A. Inhibition of the anti-apoptotic PI(3)K/Akt/Bad pathway by stress. Genes Dev 1998; 12(13):1941-6. (Pubitemid 28323868)
37. Schutze S, Potthoff K, Machleidt T et al. TNF activates NF-kB by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell 1992; 71:765-76.
38. Kashkar H, Wiegmann K, Yazdanpanah B et al. Acid sphingomyelinase is indispensable for UV light-induced Bax conformational change at the mitochondrial membrane. J Biol Chem 2005; 280(21):20804-13. (Pubitemid 40776785)
39. Yu ZF, Nikolova-Karakashian M, Zhou D et al. Pivotal role for acidic sphingomyelinase in cerebral ischemia-induced ceramide and cytokine production and neuronal apoptosis. J Mol Neurosci 2000; 15(2):85-97. (Pubitemid 32108678)
40. Schissel S, Keesler G, Schuchman E et al. The cellular trafficking and zinc dependence of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene. J Biol Chem 1998; 273:18250-9. (Pubitemid 28334747)
41. Sathishkumar S, Boyanovsky B, Karakashian AA et al. Elevated sphingomyelinase activity and ceramide concentration in serum of patients undergoing high dose spatially fractionated radiation treatment: Implications for endothelial apoptosis. Cancer Biol Ther 2005; 4(9):979-86. (Pubitemid 41598594)
42. Wright K, Messing E, Reeder J. Increased expression of the acid sphingomyelinase-like protein ASML3a in bladder tumors. J Urol 2002; 168:2645-9. (Pubitemid 35402709)
43. Nilsson A. The presence of spingomyelin- and ceramide-cleaving enzymes in the small intestinal tract. Biochim Biophys Acta 1969; 176(2):339-47.
44. Duan RD. Alkaline sphingomyelinase: An old enzyme with novel implications. Biochim Biophys Acta 2006; 1761(3):281-91.
45. Duan RD. Anticancer compounds and sphingolipid metabolism in the colon. In Vivo 2005; 19(1):293-300.
46. Bose R, Verheij M, Haimovitz-Friedman A et al. Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals. Cell 1995; 82(3):405-14.
47. Son JH, Yoo HH, Kim DH. Activation of de novo synthetic pathway of ceramides is responsible for the initiation of hydrogen peroxide-induced apoptosis in HL-60 cells. J Toxicol Environ Health A 2007; 70(15-16):1310-8. (Pubitemid 47124012)
48. Petrache I, Natarajan V, Zhen L et al. Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med 2005; 11:491-8. (Pubitemid 40685971)
49. Turpin S, Lancaster G, Darby I et al. Apoptosis in skeletal muscle myotubes is induced by ceramides and is positively related to insulin resistance. Am J Physiol Endocrinol Metab 2006; 291:E1341-350. (Pubitemid 44904043)
50. Itoh G, Tamura J, M S et al. DNA fragmentation of human infarcted myocardial cells demonstrated by the nick end labeling method and DNA agarose gel electrophoresis. Am J Pathol 1995; 146:1325-31.
51. Seumois G, Fillet M, Gillet L et al. De novo C16- and C24-ceramide generation contributes to spontaneous neutrophil apoptosis. J Leukoc Biol 2007; 81:1477-86. (Pubitemid 46827970)
52. Itoh Y, Yano T, Sendo T et al. Involvement of de novo ceramide synthesis in radiocontrast-induced renal tubular cell injury. Kidney Int 2006; 69:288-97. (Pubitemid 43323079)
53. Moussavi M, Assi K, Gomez-Munoz A et al. Curcumin mediates ceramide generation via the de novo pathway in colon cancer cells. Carcinogenesis 2006; 27(8):1636-44. (Pubitemid 44288053)
54. Signorelli P, Ghidoni R. Resveratrol as an anticancer nutrient: Molecular basis, open questions and promises. J Nutr Biochem 2005; 16:449-66. (Pubitemid 41039220)
55. Scarlatti F, Sala G, Somenzi G et al. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J 2003; 17(15):2339-41. (Pubitemid 39561486)
56. Chan T, Morin P, Vogelstein B et al. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998; 95:681-6. (Pubitemid 28083803)
57. Ruvolo PP, Clark W, Mumby M et al. A functional role for the B56 alpha-subunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function. J Biol Chem 2002; 277(25):22847-52. (Pubitemid 34967266)
58. Stoica BA, Movsesyan VA, Lea PMt et al. Ceramide-induced neuronal apoptosis is associated with dephosphorylation of Akt, BAD, FKHR, GSK-3beta and induction of the mitochondrial-dependent intrinsic caspase pathway. Mol Cell Neurosci 2003; 22(3):365-82. (Pubitemid 36407599)
59. von Haefen C, Wieder T, Gillissen B et al. Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells. Oncogene 2002; 21(25):4009-19. (Pubitemid 34679242)
60. Kolesnick R, Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene 2003; 22(37):5897-906. (Pubitemid 37176710)
61. 2+: A control point for apoptosis. Science 2003; 300(5616):135-9. (Pubitemid 36423046)
62. Kim HJ, Mun JY, Chun YJ et al. Bax-dependent apoptosis induced by ceramide in HL-60 cells. FEBS Lett 2001; 505(2):264-8. (Pubitemid 32896678)
63. Boise L, González-García M, Postema C et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74:579-608.
64. Chalfant C, Rathman K, Pinkerman R et al. De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J Biol Chem 2002; 277:12587-95. (Pubitemid 34952617)
65. Heinrich M, Wickel M, Schneider-Brachert W et al. Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO J 1999; 18(19):5252-63. (Pubitemid 29465576)
66. Heinrich M, Neumeyer J, Jakob M et al. Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. Cell Death Differ 2004; 11(5):550-63. (Pubitemid 38660140)
67. Grassme H, Jekle A, Riehle A et al. CD95 signaling via ceramide-rich membrane rafts. J Biol Chem 2001; 276(23):20589-96.
68. Kilkus J, Goswami R, Testai FD et al. Ceramide in rafts (detergent-insoluble fraction) mediates cell death in neurotumor cell lines. J Neurosci Res 2003; 72(1):65-75. (Pubitemid 36373812)
69. Spiegel S, AH Merrill J. Sphingolipid metabolism and cell growth regulation. FASEB J 1996; 10:1388-97. (Pubitemid 26347873)
70. Yatomi Y, Ohmori T, Rile G et al. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood 2000; 96(10):3431-8.
71. Radeff-Huang J, Seasholtz TM, Matteo RG et al. G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J Cell Biochem 2004; 92(5):949-66. (Pubitemid 44264244)
72. Hobson JP, Rosenfeldt HM, Barak LS et al. Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science 2001; 291(5509):1800-3. (Pubitemid 32198987)
73. Brinkmann V, Cyster J, Hla T. FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004; 4:1019-25. (Pubitemid 38868590)
74. Spiegel S, Milstien S. Functions of a new family of sphingosine-1- phosphate receptors. Biochim Biophys Acta 2000; 1484(2-3):107-16. (Pubitemid 30175961)
75. Hla T, Lee MJ, Ancellin N et al. Lysophospholipids-receptor revelations. Science 2001; 294(5548):1875-8.
76. Payne SG, Milstien S, Spiegel S. Sphingosine-1-phosphate: Dual messenger functions. FEBS Lett 2002; 531(1):54-7. (Pubitemid 35232784)
77. Xia P, Gamble JR, Wang L et al. An oncogenic role of sphingosine kinase. Curr Biol 2000; 10(23):1527-30. (Pubitemid 32003646)
78. Visentin B, Vekich J, Sibbald B et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion and angiogenesis in multiple tumor lineages. Cancer Cell 2006; 9:225-38. (Pubitemid 43357948)
79. Cuvillier O, Levade T. Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria. Blood 2001; 98:2828-36.
80. Goetzl E, Kong Y, Mei B. Lysophosphatidic acid and sphingosine 1-phosphate protection of T-cells from apoptosis in association with suppression of Bax. J Immunol 1999; 162(4):2049-56. (Pubitemid 29288824)
81. Cuvillier O, Rosenthal DS, Smulson ME et al. Sphingosine 1-phosphate inhibits activation of caspases that cleave poly(ADP-ribose) polymerase and lamins during Fas- and ceramide- mediated apoptosis in Jurkat T-lymphocytes. J Biol Chem 1998; 273(5):2910-6. (Pubitemid 28133941)
82. Betito S, Cuvillier O. Regulation by sphingosine 1-phosphate of Bax and Bad activities during apoptosis in a MEK-dependent manner. Biochem Biophys Res Commun 2006; 340(4):1273-7. (Pubitemid 43083415)
83. Taha TA, Kitatani K, Bielawski J et al. Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism. J Biol Chem 2005; 280(17):17196-202. (Pubitemid 41389186)
84. Liu H, Toman RE, Goparaju S et al. Sphingosine kinase type 2 is a putative BH3-Only protein that induces apoptosis. J Biol Chem 2003; 278:40330-6. (Pubitemid 37248601)
85. Le Stunff H, Giussani P, Maceyka M et al. Recycling of sphingosine is regulated by the concerted actions of sphingosine-1-phosphate phosphohydrolase 1 and sphingosine kinase 2. J Biol Chem 2007; 282:34372-80. (Pubitemid 350159464)
86. Spiegel S, Milstien S. Functions of the multifaceted family of sphingosine kinases and some close relatives. J Biol Chem 2006.
87. Woodgett JR. Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 2005; 17(2):150-7. (Pubitemid 40380938)
88. Ruggero D, Sonenberg N. The Akt of translational control. Oncogene 2005; 24(50):7426-34. (Pubitemid 41637982)
89. Tohma Y, Gratas C, Biernat W et al. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 1998; 57(7):684-9. (Pubitemid 28335057)
90. Carpten JD, Faber AL, Horn C et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007; 448(7152):439-44. (Pubitemid 47123510)
91. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2(7):489-501. (Pubitemid 37328931)
92. Fox TE, Houck KL, O'Neill SM et al. Ceramide recruits and activates protein kinase C zeta (PKC zeta) within structured membrane microdomains. J Biol Chem 2007; 282(17):12450-7. (Pubitemid 47100622)
93. Powell DJ, Hajduch E, Kular G et al. Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol Cell Biol 2003; 23(21):7794-808. (Pubitemid 37271476)
94. Salinas M, Lopez-Valdaliso R, Martin D et al. Inhibition of PKB/Akt1 by C2-ceramide involves activation of ceramide-activated protein phosphatase in PC12 cells. Mol Cell Neurosci 2000; 15(2):156-69. (Pubitemid 30109119)
95. Stratford S, Hoehn K, Liu F et al. Regulation of insulin action by ceramide: Dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J Biol Chem 2004; 279:36608-15. (Pubitemid 39129005)
96. Law B, Rossie S. The dimeric and catalytic subunit forms of protein phosphatase 2A from rat brain are stimulated by C2-ceramide. J Biol Chem 1995; 270(21):12808-13.
97. Dobrowsky R, Kamibayashi C, Mumby M et al. Ceramide activates a heterotrimeric protein phosphatase 2A. J Biol Chem 1993; 268(21):15523-30. (Pubitemid 23222045)
98. Dey R, Majumder N, Bhattacharjee S et al. Leishmania donovani-induced ceramide as the key mediator of Akt dephosphorylation in murine macrophages: Role of protein kinase Czeta and phosphatase. Infect Immun 2007; 75:2136-42. (Pubitemid 46744299)
99. Schmitz-Peiffer C, Craig D, Biden T. Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J Biol Chem 1999; 274:24202-10.
100. Guan L, Song K, Pysz M et al. Protein kinase C-mediated down-regulation of cyclin D1 involves activation of the translational repressor 4E-BP1 via a phosphoinositide 3-kinase/Akt-independent, protein phosphatase 2A-dependent mechanism in intestinal epithelial cells. J Biol Chem 2007; 282:14213-25. (Pubitemid 47100475)
101. Goswami R, Singh D, Phillips G et al. Ceramide regulation of the tumor suppressor phosphatase PTEN in rafts isolated from neurotumor cell lines. J Neurosci Res 2005; 81:541-50. (Pubitemid 41297391)
102. Gómez-Muñoz A, Kong J, Parhar K et al. Ceramide-1-phosphate promotes cell survival through activation of the phosphatidylinositol 3-kinase/protein kinase B pathway. FEBS Lett 2005; 579:3744-50. (Pubitemid 40897719)
103. Means C, Xiao C, Li Z et al. Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2007; 292:H2944-H2951. (Pubitemid 47084545)
104. Igarashi J, Bernier SG, Michel T. Sphingosine 1-phosphate and activation of endothelial nitric-oxide synthase. differential regulation of Akt and MAP kinase pathways by EDG and bradykinin receptors in vascular endothelial cells. J Biol Chem 2001; 276(15):12420-6.
105. Levine Y, Li G, Michel T. Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells. Evidence for an AMPK - Rac1 - Akt - endothelial nitric-oxide synthase pathway. J Biol Chem 2007; 282:20351-64. (Pubitemid 47100039)
106. Fieber C, Eldgridge J, Taha T et al. Modulation of total Akt kinase by increased expression of a single isoform: Requirement of the sphingosine-1-phosphate receptor Edg3/S1P3, for the VEGF-dependent expression of Akt3 in primary endothelial cells. Exp Cell Res 2006; 312:1164-73.
107. Tanimoto T, Jin ZG, Berk BC. Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). J Biol Chem 2002; 277(45):42997-3001. (Pubitemid 35285679)
108. Limaye V, Li X, Hahn C et al. Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members. Blood 2005; 105:3169-77.
109. Banno Y, Takuwa Y, Akao Y et al. Involvement of phospholipase D in sphingosine 1-phosphate-induced activation of phosphatidylinositol 3-kinase and Akt in Chinese hamster ovary cells overexpressing EDG3. J Biol Chem 2001; 276:35622-8.
110. Igarashi J, Michel T. Sphingosine 1-phosphate and isoform-specific activation of phosphoinositide 3-kinase beta. Evidence for divergence and convergence of receptor-regulated endothelial nitric-oxide synthase signaling pathways. J Biol Chem 2001; 276:36281-8.
111. Baudhuin LM, Jiang Y, Zaslavsky A et al. S1P3-mediated Akt activation and cross-talk with platelet-derived growth factor receptor (PDGFR). Faseb J 2004; 18(2):341-3.
112. Baudhuin L, Cristina K, Lu J et al. Akt activation induced by lysophosphatidic acid and sphingosine-1-phosphate requires both mitogen-activated protein kinase kinase and p38 mitogen-activated protein kinase and is cell-line specific. Mol Pharmacol 2002; 62:660-71. (Pubitemid 36329385)
113. Sanchez T, Skoura A, Wu M et al. Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. Arterioscler Thromb Vasc Biol 2007; 27:1312-8. (Pubitemid 46809419)
114. Liang C, Feng P, Ku B et al. Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nat Cell Biol 2006; 8:688-99.
115. Mizushima N. Autophagy: Process and function. Genes Dev 2007; 21(22):2861-73. (Pubitemid 350133435)
116. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124(3):471-84. (Pubitemid 43199434)
117. Takeuchi H, Kondo Y, Fujiwara K et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 2005; 65(8):3336-46. (Pubitemid 40524618)
118. Scarlatti F, Bauvy C, Ventruti A et al. Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. J Biol Chem 2004; 279:18384-91. (Pubitemid 38623254)
119. Patschan S, Chen J, Polotskaia A et al. Lipid mediators of autophagy in stress-induced premature senescence of endothelial cells. Am J Physiol Heart Circ Physiol 2008; 294:H1119-H29.
120. Daido S, Kanzawa T, Yamamoto A et al. Pivotal role of the cell death factor BNIP3 in ceramide-induced autophagic cell death in malignant glioma cells. Cancer Res 2004; 64(12):4286-93. (Pubitemid 38802435)
121. Lavieu G, Scarlatti F, Sala G et al. Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation. J Biol Chem 2006; 281:8518-27. (Pubitemid 43847954)
122. Boya P, Gonzalez-Polo RA, Casares N et al. Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 2005; 25(3):1025-40. (Pubitemid 40165810)
123. Verheij M, Bose R, Lin X et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996; 380:75-9. (Pubitemid 26076240)
124. Basu S, Bayoumy S, Zhang Y et al. BAD enables ceramide to signal apoptosis via Ras and Raf-1. J Biol Chem 1998; 273(46):30419-26. (Pubitemid 28545515)
125. Cuvillier O, Pirianov G, Kleuser B et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996; 381(6585):800-3. (Pubitemid 26243122)
126. Edsall LC, Cuvillier O, Twitty S et al. Sphingosine kinase expression regulates apoptosis and caspase activation in PC12 cells. J Neurochem 2001; 76(5):1573-84. (Pubitemid 32198261)
127. Usui S, Sugimoto N, Takuwa N et al. Blood lipid mediator sphingosine 1-phosphate potently stimulates platelet-derived growth factor-A and -B chain expression through S1P1-Gi-Ras-MAPK-dependent induction of Kruppel-like factor 5. J Biol Chem 2004; 279(13):12300-11. (Pubitemid 38445796)
128. Hsieh HL, Sun CC, Wu CB et al. Sphingosine 1-phosphate induces EGFR expression via Akt/NF-kappaB and ERK/AP-1 pathways in rat vascular smooth muscle cells. J Cell Biochem 2007.
129. Libermann TA, Nusbaum HR, Razon N et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985; 313(5998):144-7. (Pubitemid 15192341)
130. Kohler M, Janz I, Wintzer HO et al. The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res 1989; 9(6):1537-47.
131. Yoshida K, Tosaka A, Takeuchi S et al. Epidermal growth factor receptor content in human renal cell carcinomas. Cancer 1994; 73(7):1913-8. (Pubitemid 24101971)
132. Dbaibo G, Pushkareva M, Jayadev S et al. Retinoblastoma gene product as a downstream target for a ceramide-dependent pathway of growth arrest. Proc Natl Acad Sci USA 1995; 92:1347-51.
133. Phillips DC, Hunt JT, Moneypenny CG et al. Ceramide-induced G2 arrest in rhabdomyosarcoma (RMS) cells requires p21Cip1/Waf1 induction and is prevented by MDM2 overexpression. Cell Death Differ 2007; 14(10):1780-91. (Pubitemid 47423645)
134. Wang J, Lv XW, Shi JP et al. Mechanisms involved in ceramide-induced cell cycle arrest in human hepatocarcinoma cells. World J Gastroenterol 2007; 13(7):1129-34. (Pubitemid 46511019)
135. Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: The path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med 2006; 12(10):1133-8. (Pubitemid 44527346)
136. Greider CW, Blackburn EH. Telomeres, telomerase and cancer. Sci Am 1996; 274(2):92-7.
137. Blackburn EH, Greider CW, Henderson E et al. Recognition and elongation of telomeres by telomerase. Genome 1989; 31(2):553-60. (Pubitemid 20118437)
138. Weinrich SL, Pruzan R, Ma L et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 1997; 17(4):498-502. (Pubitemid 27518407)
139. Ogretmen B, Kraveka JM, Schady D et al. Molecular mechanisms of ceramide-mediated telomerase inhibition in the A549 human lung adenocarcinoma cell line. J Biol Chem 2001; 276(35):32506-14.
140. Wooten-Blanks LG, Song P, Senkal CE et al. Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1. FASEB J 2007; 21(12):3386-97. (Pubitemid 47565557)
141. Xu JX, Morii E, Liu Y et al. High tolerance to apoptotic stimuli induced by serum depletion and ceramide in side-population cells: High expression of CD55 as a novel character for side-population. Exp Cell Res 2007; 313(9):1877-85. (Pubitemid 46653875)
142. Ozaki H, Hla T, Lee MJ. Sphingosine-1-phosphate signaling in endothelial activation. J Atheroscler Thromb 2003; 10(3):125-31.
143. Park KS, Kim MK, Lee HY et al. S1P stimulates chemotactic migration and invasion in OVCAR3 ovarian cancer cells. Biochem Biophys Res Commun 2007; 356(1):239-44. (Pubitemid 46413154)
144. Guo XZ, Zhang WW, Wang LS et al. [Adenovirus-mediated overexpression of KAI1 suppresses sphingosine kinase activation and metastasis of pancreatic carcinoma cells]. Zhonghua Nei Ke Za Zhi 2006; 45(9):752-4.
145. Selzner M, Bielawska A, Morse MA et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 2001; 61(3):1233-40. (Pubitemid 32174448)
146. Elojeimy S, Liu X, McKillop JC et al. Role of acid ceramidase in resistance to FasL: Therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. Mol Ther 2007; 15(7):1259-63. (Pubitemid 46965321)
147. Holman DH, Turner LS, El-Zawahry A et al. Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 2008; 61(2):231-42. (Pubitemid 350160321)
148. Swanton C, Marani M, Pardo O et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007; 11(6):498-512. (Pubitemid 46856907)
149. Kawamori T, Osta W, Johnson KR et al. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J 2006; 20(2):386-8. (Pubitemid 46671180)
150. Johnson KR, Johnson KY, Crellin HG et al. Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J Histochem Cytochem 2005; 53(9):1159-66. (Pubitemid 41262984)
151. French K, Schrecengost R, Lee B et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003; 63:5962-9. (Pubitemid 37187498)
152. French K, Upson J, Keller S et al. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 2006; 318:596-603. (Pubitemid 44061234)
153. Le Scolan E, Pchejetski D, Banno Y et al. Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood 2005; 106(5):1808-16. (Pubitemid 41208598)
154. Kohno M, Momoi M, Oo M et al. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol 2006; 26:7211-23. (Pubitemid 44477697)
155. Oskouian B, Sooriyakumaran P, Borowsky A et al. Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is downregulated in colon cancer. Proc Natl Acad Sci USA 2006; 103:17384-9. (Pubitemid 44788978)
156. Symolon H, Schmelz E, Dillehay D et al. Dietary soy sphingolipids suppress tumorigenesis and gene expression in 1,2-dimethylhydrazine-treated CF1 mice and ApcMin/+ mice. J Nutr 2004; 134:1157-61. (Pubitemid 38619956)
157. Schmelz EM, Dillehay DL, Webb SK et al. Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in CF1 mice treated with 1,2-dimethylhydrazine: Implications for dietary sphingolipids and colon carcinogenesis. Cancer Res 1996; 56(21):4936-41. (Pubitemid 26374432)
158. Schmelz EM, Roberts PC, Kustin EM et al. Modulation of intracellular beta-catenin localization and intestinal tumorigenesis in vivo and in vitro by sphingolipids. Cancer Res 2001; 61(18):6723-9. (Pubitemid 32896494)
159. Bonhoure E, Pchejetski D, Aouali N et al. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia 2006; 20(1):95-102.
160. Bektas M, Jolly PS, Muller C et al. Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: Role of Bcl-2 expression. Oncogene 2005; 24(1):178-87. (Pubitemid 40143877)
161. Schindler T, Bornmann W, Pellicena P et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289(5486):1938-42.
162. Baran Y, Salas A, Senkal CE et al. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 2007; 282(15):10922-34. (Pubitemid 47100788)
163. Bittman R. Synthetic sphingolipids as bioactive molecules: Roles in regulation of cell function. In: Wiley, editor. Wiley Encyclopedia 2008.
164. McCormack P, Goa K. Miglustat. Drugs 2003; 63:2427-36.
165. Weiss M, Hettmer S, Smith P et al. Inhibition of melanoma tumor growth by a novel inhibitor of glucosylceramide synthase. Cancer Res 2003; 63(13):3654-8. (Pubitemid 36793049)
166. Guerrera M, Ladisch S. N-butyldeoxynojirimycin inhibits murine melanoma cell ganglioside metabolism and delays tumor onset. Cancer Lett 2003; 201(1):31-40. (Pubitemid 37297995)
167. Dbaibo GS, Kfoury Y, Darwiche N et al. Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity. Haematologica 2007; 92(6):753-62. (Pubitemid 350155300)
168. Billich A, Bornancin F, Mechtcheriakova D et al. Basal and induced sphingosine kinase 1 activity in A549 carcinoma cells: Function in cell survival and IL-1beta and TNF-alpha induced production of inflammatory mediators. Cell Signal 2005; 17:1203-17. (Pubitemid 40982611)
169. Gamble J, Xia P, Hahn C et al. Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects. Int J Cancer 2006; 118:2412-20.
170. Leroux M, Auzenne E, Evans R et al. Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells. Prostate 2007; 67:1699-717. (Pubitemid 350036956)
171. Leroux ME, Auzenne E, Evans R et al. Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells. Prostate 2007; 67(15):1699-717. (Pubitemid 350036956)
172. Yasui H, Hideshima T, Raje N et al. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res 2005; 65(16):7478-84. (Pubitemid 41161283)
173. Sani BP, Shealy YF, Hill DL. N-(4-hydroxyphenyl)retinamide: Interactions with retinoid-binding proteins/ receptors. Carcinogenesis 1995; 16(10):2531-4.
174. Sheikh MS, Shao ZM, Li XS et al. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis 1995; 16(10):2477-86.
175. Wang H, Maurer BJ, Reynolds CP et al. N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res 2001; 61(13):5102-5. (Pubitemid 32681541)
176. Maurer BJ, Melton L, Billups C et al. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 2000; 92(23):1897-909. (Pubitemid 32036920)
177. Erdreich-Epstein A, Tran LB, Bowman NN et al. Ceramide signaling in fenretinide-induced endothelial cell apoptosis. J Biol Chem 2002; 277(51):49531-7. (Pubitemid 36014391)
178. Kraveka J, Li L, Szulc Z et al. Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells. J Biol Chem 2007; 282:16718-28. (Pubitemid 47093220)
179. Jiang Q, Wong J, Fyrst H et al. gamma-Tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis. Proc Natl Acad Sci USA 2004; 101(51):17825-30. (Pubitemid 40051971)
180. Morales PR, Dillehay DL, Moody SJ et al. Safingol toxicology after oral administration to TRAMP mice: Demonstration of safingol uptake and metabolism by N-acylation and N-methylation. Drug Chem Toxicol 2007; 30(3):197-216. (Pubitemid 47026913)
181. Grammatikos G, Teichgraber V, Carpinteiro A et al. Overexpression of acid sphingomyelinase sensitizes glioma cells to chemotherapy. Antioxid Redox Signal 2007; 9(9):1449-56. (Pubitemid 47255025)
182. Won JS, Singh I. Sphingolipid signaling and redox regulation. Free Radic Biol Med 2006; 40(11):1875-88. (Pubitemid 43728861)
183. Andersson D, Cheng Y, Duan RD. Ursolic acid inhibits the formation of aberrant crypt foci and affects colonic sphingomyelin hydrolyzing enzymes in azoxymethane-treated rats. J Cancer Res Clin Oncol 2008; 134(1):101-7. (Pubitemid 350060690)
184. Rosato RR, Maggio SC, Almenara JA et al. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury and the acid sphingomyelinase-dependent generation of ceramide. Mol Pharmacol 2006; 69(1):216-25. (Pubitemid 43048908)
185. Darroch PI, Dagan A, Granot T et al. A lipid analogue that inhibits sphingomyelin hydrolysis and synthesis, increases ceramide and leads to cell death. J Lipid Res 2005; 46(11):2315-24. (Pubitemid 41532520)
186. Suomalainen L, Hakala JK, Pentikainen V et al. Sphingosine-1-phosphate in inhibition of male germ cell apoptosis in the human testis. J Clin Endocrinol Metab 2003; 88(11):5572-9. (Pubitemid 37452771)
187. Pchejetski D, Kunduzova O, Dayon A et al. Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ Res 2007; 100(1):41-9. (Pubitemid 46066772)